A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07677254 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 17111
Last updated 2026-07-16
Summary
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Conditions
- Prostatic Neoplasms, Castration-Resistant
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Max Age
- 115 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-30
- Primary Completion
- 2026-11-30
- Completion
- 2026-11-30
Countries
- United States
Study Locations
More Related Trials
-
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07287150 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
NCT02066961 ·Status: COMPLETED
-
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236 ·Status: RECRUITING ·Phase: PHASE1
-
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
NCT06145633 ·Status: RECRUITING ·Phase: PHASE2
-
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
NCT03835533 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
NCT01834651 ·Status: COMPLETED ·Phase: PHASE2
-
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT04631744 ·Status: TERMINATED ·Phase: PHASE2
-
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT01718353 ·Status: COMPLETED ·Phase: PHASE2
-
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
NCT02566772 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841 ·Status: RECRUITING ·Phase: PHASE1
-
Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer
NCT04801186 ·Status: COMPLETED
-
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
NCT04506567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of FT-7051 in Men With MCRPC
NCT04575766 ·Status: TERMINATED ·Phase: PHASE1
-
PROCARE - PROstate Cancer Real World Evidence Registry
NCT06835218 ·Status: RECRUITING
-
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
NCT00510718 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
NCT02787005 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
NCT07476001 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT05241613 ·Status: TERMINATED ·Phase: PHASE1
-
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
NCT00757757 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
NCT01734681 ·Status: WITHDRAWN ·Phase: PHASE2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
NCT07025512 ·Status: WITHDRAWN ·Phase: PHASE2
-
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
NCT02091531 ·Status: COMPLETED ·Phase: PHASE2